Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins From Vybion, Inc.

Posted on: Tuesday, 13 May 2008, 15:00 CDT Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future... [read full story]                    

Add Comment
There are also 7 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies